New molecularly targeted therapies are available for some types of breast cancer. However, for one type of breast cancer, called triple negative, targeted therapies are not yet available. This project aims to test new targeted therapies that may be effective against triple negative breast cancer.
A new anti-cancer targeted therapy will be tested alone and in combination with other drug therapies, to determine if they kill or stop the growth of cancer cells. The testing will be performed using cell line models of triple negative breast cancer grown under laboratory conditions. We will also attempt to identify potential biomarkers in the cancer cells that may predict sensitivity to these therapies.
The goal of this project is to identify new anti-cancer therapies for further testing in clinical trials in patients with triple negative breast cancer.
